spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  iloperidone 

 HSMN NewsFeed - 21 Jul 2017
Vanda Receives Negative Opinion for Marketing Authorization from the European Medicines Agency on Fanaptum(TM) for the Treatment of Schizophrenia
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 8 Dec 2016
Vanda Pharmaceuticals Settles Fanapt(R) Patent Litigation with Apotex
Biopharmaceuticals Generics Litigation Licensing
 HSMN NewsFeed - 11 Jan 2010
Novartis Launches Schizophrenia Treatment Fanapt in the US, Offering Patients an Attractive Alternative to Existing Medications
Biopharmaceuticals
 HSMN NewsFeed - 12 Oct 2009
Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
Biopharmaceuticals Licensing
 HSMN NewsFeed - 12 Oct 2009
Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
Biopharmaceuticals Licensing
 HSMN NewsFeed - 7 May 2009
Vanda Pharmaceuticals Announces Withdrawal of Director Nominees and Proposal to Liquidate Submitted by Tang Capital
Biopharmaceuticals
 HSMN NewsFeed - 28 Jul 2008
FDA Issues Not Approvable Letter for Iloperidone to Vanda Pharmaceuticals
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Jul 2008
Vanda Pharmaceuticals Announces Receipt of Not Approvable Letter From FDA for Iloperidone
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 Jun 2008
Phase III Data Show Vanda Pharmaceuticals' Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
Biopharmaceuticals
 HSMN NewsFeed - 13 Dec 2007
Iloperidone Phase III Clinical Data Demonstrate Efficacy and Favorable Safety and Tolerability Profile
Biopharmaceuticals
 HSMN NewsFeed - 12 Dec 2007
Vanda Presents Phase III Iloperidone Efficacy Data
Biopharmaceuticals
 HSMN NewsFeed - 23 Oct 2007
Vanda Pharmaceuticals Hires Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Sep 2007
Vanda Pharmaceuticals Submits Iloperidone New Drug Application
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 Sep 2007
Titan Adds Dr. Marc Rubin to Executive Management Team as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Jun 2007
Vanda Pharmaceuticals Announces Board Changes
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 7 Dec 2006
Vanda Pharmaceuticals Confirms Iloperidone Efficacy With Positive Phase III Clinical Trial Results in Schizophrenia
Biopharmaceuticals
 HSMN NewsFeed - 15 Nov 2006
Vanda Pharmaceuticals' VEC-162 Demonstrates Positive Results in a Phase III Transient Insomnia Clinical Trial
Biopharmaceuticals
 HSMN NewsFeed - 6 Jul 2006
Vanda Pharmaceuticals Names Dr. Paolo Baroldi Chief Medical Officer
Biopharmaceuticals Neurology Personnel
Return to NewsFeed  

 Additional items found! 1

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 1 additional stories matching:
iloperidone
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.